By acting on the smooth muscle of the coronary and peripheral blood vessels and the atrioventricular node, inhibiting the influx of Ca2 into the cells, it shows the effect of vasodilation and prolonging the conduction time of the atrioventricular node, thus being effective for hypertension, arrhythmia, and angina pectoris. 1. Effect on blood pressure: It can reduce hypertension under anesthesia or without anesthesia; while lowering blood pressure, it can reduce peripheral vascular resistance and myocardial oxygen consumption, and increase cardiac output; while not reducing the blood flow to the brain, coronary arteries, and kidneys, it can lower blood pressure and show a sodium diuretic effect. 2. Effect on arrhythmia: It prolongs the conduction time, effective refractory period, and functional refractory period of the atrioventricular node, and shows an effect on supraventricular tachyarrhythmia; it inhibits supraventricular tachyarrhythmia caused by atrial electrical stimulation. 3. Effect on myocardial ischemia: It improves the balance of myocardial oxygen supply and demand, dilates the main and side branches of the coronary arteries, increases blood flow to the ischemic part of the myocardium, and inhibits coronary artery spasm; it has a myocardial protective effect, inhibits excessive influx of Ca2 into cells during myocardial ischemia, maintains cardiac function, myocardial energy metabolism, and shrinks the infarct focus.

A coenzyme for acetylation reactions in the body. It participates in acetylation reactions in the body and plays an important role in the metabolism of sugar, fat and protein, such as the tricarboxylic acid cycle, liver glycogen accumulation, acetylcholine synthesis, lowering cholesterol, regulating blood lipid content and synthesizing steroid substances, which are all closely related to this product.

This product is a monoquaternary ammonium steroid medium-acting non-depolarizing muscle relaxant, similar in structure to pancuronium bromide, which blocks the conduction between nerve endings and striated muscles by competing with acetylcholine for nicotinic receptors located at the motor end plate of striated muscles. Unlike depolarizing neuromuscular blocking drugs such as succinylcholine, this product does not cause muscle fiber bundles to tremble. Intravenous injection of 0.08-0.1mg/kg is effective within 1 minute, reaching a peak in 3-5 minutes, and maintaining for 30-90 minutes. The muscle relaxant effect is 3 times stronger than that of tubocurarine chloride; it has no vagus nerve blocking effect. Since vecuronium bromide does not cause an increase in heart rate, it is suitable for patients with myocardial ischemia and heart disease, but the use of vagus nerve excitants and β-receptor blockers is prone to bradycardia. This product has a weak histamine release effect, and there are also bronchospasm and allergic reactions, but they are rare.

1. Inhibit plasminogen activators, so that plasminogen cannot be activated into plasmin, thereby inhibiting the dissolution of fibrin and producing a hemostatic effect; 2. Promote the release of active substances by platelets, enhance platelet aggregation and adhesion, shorten coagulation time, and produce a hemostatic effect; 3. Enhance capillary resistance, reduce capillary permeability, and thus reduce bleeding.

This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, and also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pneumoniae, Mycoplasma pneumoniae, and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.